JPMorgan Chase & Co. Purchases 52,097 Shares of Quanterix Co. (NASDAQ:QTRX)

JPMorgan Chase & Co. boosted its stake in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 23.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 270,054 shares of the company's stock after acquiring an additional 52,097 shares during the quarter. JPMorgan Chase & Co. owned 0.70% of Quanterix worth $2,871,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Bank of New York Mellon Corp lifted its holdings in Quanterix by 1.8% in the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after buying an additional 1,963 shares during the period. American Century Companies Inc. lifted its holdings in Quanterix by 9.1% in the 4th quarter. American Century Companies Inc. now owns 71,992 shares of the company's stock worth $765,000 after buying an additional 6,023 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Quanterix in the 4th quarter worth approximately $66,000. Janney Capital Management LLC lifted its holdings in Quanterix by 40.9% in the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company's stock worth $353,000 after buying an additional 9,639 shares during the period. Finally, Peapack Gladstone Financial Corp purchased a new stake in Quanterix in the 3rd quarter worth approximately $131,000. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Quanterix Stock Performance

Shares of QTRX stock traded down $0.10 during mid-day trading on Monday, hitting $5.78. The company's stock had a trading volume of 548,324 shares, compared to its average volume of 546,556. The stock has a market cap of $224.20 million, a price-to-earnings ratio of -5.45 and a beta of 1.35. The business has a 50-day moving average price of $6.50 and a 200 day moving average price of $9.48. Quanterix Co. has a 52-week low of $4.67 and a 52-week high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The business had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. Equities research analysts predict that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on QTRX. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Canaccord Genuity Group lowered their price objective on Quanterix from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.